Compare Ulta Beauty Inc (ULTA) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ulta Beauty Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Ulta Beauty Inc trades at $570 (market cap $24.12B), while State Street SPDR S&P Biotech ETF trades at $154.12 (market cap $10.11B). The key difference: Ulta Beauty Inc is far larger — about 2.4× State Street SPDR S&P Biotech ETF's market cap, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Ulta Beauty Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Ulta Beauty Inc for 92 Days and State Street SPDR S&P Biotech ETF for 37 Days on average.
| ULTA | XBI | |
|---|---|---|
Market Cap | $24.12B | $10.11B |
Volume | 457,598 | 12,903,266 |
Sector | Consumer Cyclical | Broad Market / Factor |
52-Week High | $706.82 | $169.55 |
52-Week Low | $450.75 | $104.99 |
Typical Hold Time | 92 Days | 37 Days |
Enterprise Value | $26.43B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ULTA Beauty trades at $545.48, down 0.33% on the day, with a bullish technical outlook supported by moving averages. The company reported strong Q2 2026 earnings beat and raised 2026 guidance, though Q4 2025 missed expectations. Valuation metrics show a P/E of 20.55 and P/S of 1.92, with robust profitability including 46.12% ROE. Analyst consensus is strongly bullish with 59.57% buy ratings and a $624.93 price target, representing 14.6% upside potential.
ULTA presents a compelling growth story with e-commerce momentum and expansion into wellness categories, though margin compression and flat traffic pose near-term challenges. The stock offers attractive upside to analyst targets but faces execution risks amid consumer spending pressures. Institutional ownership remains strong with recent buying activity from major funds.
XBI trades at $153.34, up 2.07% today, but faces bearish technical signals with 17 sell indicators versus 4 buys. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from recent M&A activity and positive clinical trial catalysts. Current price sits near resistance at $154, with support at $147.
Biotech sector optimism is growing with cancer vaccine breakthroughs and improved capital access, though XBI's 0.35% expense ratio is higher than broader healthcare ETFs. Key risks include sector volatility and regulatory uncertainty, while analyst consensus remains neutral with 100% hold rating.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Ulta Beauty Inc
With more than 1,300 stores and a partnership with Target, Ulta Beauty is the largest specialized beauty retailer in the U.S. The firm offers makeup (43% of 2021 sales), fragrances, skin care, and hair care products (20% of 2021 sales), and bath and body items. Ulta offers private-label products and merchandise from more than 500 vendors. It also offers salon services, including hair, makeup, skin, and brow services, in all stores. Most Ulta stores are approximately 10,000 square feet and are in suburban strip centers. Ulta was founded in 1990 and is based in Bolingbrook, Illinois.
Read more on ULTA →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
